Abstract: Compounds of formula (I): wherein: X represents an oxygen or a sulphur or CH2 or R1 and R2 represent a hydrogen atom, or a group as defined in the description, A represents an alkylene chain as described in the description, B is as defined in the description, R3 and R4 represent a hydrogen atom or a group as defined in the description, D represents an optionally substituted benzene, optionally substituted pyrazine, optionally substituted pyrimidine or optionally substituted pyridazine and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.

Abstract: Compounds of formula (I): wherein: R1 represents an optionally substituted heteroaryl group, R2 represents an optionally substituted cycloalkyl group, R3 represents a hydrogen atom or an alkyl group, and R4 and R5 are as defined in the description, and Medicinal products containing the same are useful in the treatment of non-insulin-dependent type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof.

Abstract: The invention concerns compounds of formula (I): R-A-R? wherein: A is as defined in the description; R represents a group (V), (VI), (VII) or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R? represents a —(CH2)t-R5 group wherein t and R5 are as defined in the description.

Abstract: Compound of formula (I): wherein: R1 and R2, which may be identical or different, each represents hydrogen, acyl or alkyl, Ar represents aryl or heteroaryl, A represents a group selected from: R4 represents hydrogen or alkyl, R5 represents hydrogen, alkyl, aryl or heteroaryl, R3 represents aryl, heteroaryl, dicyclopropylmethyl or benzhydryl, or A-R3 represents an optionally substituted naphthyl group, with the exclusion of 2,5-dihydroxy-3-(4-methoxyphenyl)-6-(2-phenylethenyl)-1,4-benzoquinone, 2,5-dihydroxy-3-(4-methoxyphenyl)-6-(2-naphthyl)-1,4-benzoquinone and 2,5-dihydroxy-3-(2-naphthyl)-6-phenyl-1,4-benzoquinone. Medicinal products containing the same which are useful in the treatment of diseases associated with a deregulation of glycaemia.

Abstract: A compound selected from these of formula (I): wherein: R1 represents hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, heterocycloalkoxycarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl or phosphono, R2 represents oxygen or sulphur, R3 represents hydrogen or alkyl, cycloalkyl or arylalkyl, X represents linear or branched (C1-C6)alkylene, R4 represents a group selected from amino optionally substituted by one or two groups, —N(R3)—X1—OR5 wherein R3, X1 and R5 are as defined in the description, —N(R3)—X1—NR6R7 wherein R3, X1, R6 and R7 are as defined in the description, hydroxy, alkoxy, aryloxy, —O—X1—OR5 wherein R5 and X1 are as defined in the description, and —O—X1—NR6R7 wherein R6, R7 and X1 are as defined in the description, its isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base, and medical products containing the same which are useful in the treatment of cancer.

Abstract: Compounds of formula (I): wherein: R1 represents an optionally substituted heteroaryl group, R2 represents an optionally substituted cycloalkyl group, R3 represents a hydrogen atom or an alkyl group, and R4 and R5 are as defined in the description, and Medicinal products containing the same are useful in the treatment of non-insulin-dependent type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof.

Abstract: The invention concerns compounds of formula (I): R—A—R? wherein: A is as defined in the description; R represent, a group (V), wherein R?a and R?a are as defined in the description, or R forms with A a cyclic structure as defined in the description; R? represents a (CH2)t—R2 group wherein q, t, and R2 are as defined in the description. The invention is useful for preparing medicines.

Abstract: The invention concerns compounds of formula (I): R-A-R? wherein: A is as defined in the description; R represents a group (V), (VI), (VII) or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R? represents a —(CH2)t-R5 group wherein t and R5 are as defined in the description.

Abstract: Compounds of formula (I): wherein: X represents oxygen or sulphur or a group CH2 or R1, R2, R3, R4, R5 and R6 are as defined in the description, A represents an alkylene chain as defined in the description, B represents alkyl or alkenyl substituted by a group ?or R9, or B represents a group ?or R9, D represents a benzene, pyridine, pyrazine, pyrimidine or pyridazine nucleus.

Abstract: The invention relates to a compound of formula (I): wherein: A represents pyridine, pyridinium or piperidine R1, R2, R3 and R4 the are as defined in the description R5 represents hydrogen, a nitrogen-containing heterocycle or a group of formula (II): R6 represents hydrogen or linear or branched (C1-C6)alkyl. and medicinal products containing the same which are useful in treating pain or deficiencies in memory.

Abstract: A compound selected from those of formula (I): 1

Abstract: Compound of formula (I): 1

Abstract: The invention relates to a method of manufacturing anisotropic conductive polymer film (23 and 24) on a semiconductor wafer (T) comprising, on one surface, a layer of passivation (12) in which at least one opening is made to allow access to a contact pad (11).

Abstract: A compound of formula corresponding to either formula (Ia) or (Ib): 1

Abstract: The invention relatests compound of formula (I): 1

Abstract: Compound of formula (I): 1

Abstract: A compound of formula (I): 1

Abstract: Improved vector constructs useful in the expression of double-stranded RNA are provided. The constructs are particularly useful for expression of double-stranded RNA in vitro and in vivo.

Abstract: Compounds of formula (I): 1

Abstract: Compounds of formula corresponding to either formula (Ia) or (Ib): wherein: M represents a molecule that can be used for the treatment or diagnosis of pathologies caused by attack on the cartilage, R1, R2 and R3 represent an alkyl group, or R1, R2 and R3, together with the nitrogen atom carrying them, form a heterocycle, X represents a (C1-C6)alkylene chain in which one or more —CH2— groups are optionally replaced by a sulphur atom, an oxygen atom, or an —NR—, —CO—, —CO—NH—, —CO2—, —SO— or —SO2— group, n represents 0 or 1, Hal represents a halogen atom, or, R4 represents an alkyl group, Hal represents a halogen atom, represents a molecule that can be used for the treatment or diagnosis of pathologies caused by attack on the cartilage, wherein the nitrogen atom may optionally be included in a saturated or unsaturated nitrogen-containing heterocyclic system, or i